


The Medicines Company's Cangrelor Bridge Trial Published in the Journal of the American Medical Association
January 17, 2012 16:34 ET
The Medicines Company's Cangrelor Bridge Trial Published in the Journal of the American Medical Association
PARSIPPANY, NJ--(Marketwire - Jan 17, 2012) - The Medicines Company (
The article, "Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery," is available in the January 18 JAMA issue under Original Contributions.
About Cangrelor, About the BRIDGE Trial
Cangrelor is an investigational intravenous small molecule antiplatelet agent not approved for commercial use in any market. BRIDGE is a prospective, randomized, double-blind, placebo-controlled multicenter trial which evaluated cangrelor or placebo in 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopryidine awaiting coronary artery bypass graft (CABG) surgery. The primary efficacy endpoint was platelet reactivity. The main safety endpoint was excessive CABG-surgery related bleeding. In October 2010, The Medicines Company initiated a Phase 3 clinical trial called PHOENIX to evaluate cangrelor in patients undergoing percutaneous coronary intervention (PCI).
About The Medicines Company
The Medicines Company (